United States, March 30 -- GE HealthCare announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI.Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre?existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemother...